VJHemOnc is committed to improving our service to you

SOHO 2020 | Chemotherapy-free approaches to AL amyloidosis

VJHemOnc is committed to improving our service to you

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD, Columbia University and New York Presbyterian Hospital, New York, NY, explores chemotherapy-free treatment regimes for light chain (AL) amyloidosis. Specifically discussed are daratumumab and isatuximab, both CD38 monoclonal antibodies being investigated for the treatment of AL amyloidosis, as well as venetoclax, a BCL-2 inhibitor in amyloidosis patients with an 11;14 translocation. Dr Lentzsch also elaborates on emerging therapies that target AL amyloid deposits, including the results of the Phase III VITAL study (NCT02312206) evaluating NEOD001 (Birtamimab) in patients with AL amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter